Tag Archives: NASDAQ:BPAX

Healthcare Sector Lands in Green zone; Biosante (BPAX) to Merge with ANI Pharmaceuticals while HMS (HMSY) Cuts Outlook – BPAX, HMSY, PFE, AEZS, ESMC, NUVA

Posted on October 5, 2012 by Thomas Vedder

Healthcare sector responded positively on Thursday’s trading session and sector hiked +0.69%. If we look at the top movers of the sector so AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and Escalon Medical Corp. (NASDAQ:ESMC) were major percentage gainers while major percentage …

Posted in Healthcare, Latest Headlines | Tagged AEterna Zentaris, AEZS, Biosante, BPAX, Escalon Medical, ESMC, HMS, HMSY, NASDAQ:AEZS, NASDAQ:BPAX, NASDAQ:ESMC, NASDAQ:HMSY, NASDAQ:NUVA, NUVA, NuVasive, NYSE:PFE, PFE, Pfizer | Comments Off

Dendreon (NASDAQ:DNDN) Slashes 600 Jobs to Lower Costs – DNDN, BPAX, NLNK, PPHM

Posted on July 31, 2012 by Thomas Vedder

The Seattle-based Dendreon Corporation (NASDAQ:DNDN), manufacturer of the prostate cancer medicine Provenge, reported that it would remove over 600 jobs and lower costs by $150 million during the coming 12 months as it looks to reach profitability.

Dendreon reported in …

Posted in Healthcare, Latest Headlines | Tagged BioSante Pharmaceuticals, BPAX, Dendreon, DNDN, NASDAQ:BPAX, NASDAQ:DNDN, NASDAQ:NLNK, NASDAQ:PPHM, NewLink, NLNK, Peregrine, PPHM | Comments Off

Rival Drug Approval Put Back to Dendreon (NASDAQ:DNDN) Shares Around 5%- DNDN, HGSI, ARNA, KERX, VVUS, BPAX, CTIC

Posted on May 21, 2012 by Thomas Vedder

Shares in Dendreon Corporation (NASDAQ:DNDN) dropped over 4.97% in last trading day, and reasons could include a SEC investigation into the Seattle biotech and the victory of a competitor’s prostate cancer drug.

In Friday trading, Dendreon shares were plunged another …

Posted in Healthcare, Latest Headlines | Tagged arena, ARNA, Biosante, BPAX, Cell Therapeutics, CTIC, Dendreon, DNDN, HGSI, Human Genome Sciences, KERX, Keryx, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:CTIC, NASDAQ:DNDN, NASDAQ:HGSI, NASDAQ:KERX, NASDAQ:VVUS, Vivus, VVUS | Comments Off

Arena (NASDAQ:ARNA) Climbs Around 74% Green Mountain on Advisory Panel’s Decision- ARNA, VVUS, DNDN, OREX, HGSI, BPAX, KERX,

Posted on May 14, 2012 by Geoff Noir

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) jumped around 74 percent. The moved up followed a Food and Drug Administration advisory panel’s decision, in an 18-to-4 vote, to back authorization of teh weight-loss treatment lorcaserin.

The panel’s decision came as accessible data demonstrate …

Posted in Healthcare, Latest Headlines | Tagged Arena Pharmaceuticals, ARNA, BioSante Pharmaceuticals, BPAX, Dendreon, DNDN, HGSI, Human Genome Sciences, KERX, Keryx Biopharmaceuticals, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:DNDN, NASDAQ:HGSI, NASDAQ:KERX, NASDAQ:OREX, NASDAQ:VVUS, OREX, Orexigen Therapeutics, Vivus, VVUS | Comments Off

Novavax (NASDAQ:NVAX) Shares Surges on Healthy Results- NVAX, KERX, DNDN, ARNA, BPAX, AEZS, CTIC

Posted on May 7, 2012 by Geoff Noir

Novavax Inc (NASDAQ:NVAX) shares climbed 2.22 percent to $1.38 following the firm posted Q1 results. Net loss was $7.3 million or $0.06 a share evaluated with net loss of $7.5 million or $0.07 a share in the Q1 of 2011. …

Posted in Latest Headlines | Tagged AEterna Zentaris, AEZS, Arena Pharmaceuticals, ARNA, BioSante Pharmaceuticals, BPAX, Cell Therapeutics, CTIC, Dendreon, DNDN, KERX, Keryx Biopharmaceuticals, NASDAQ:AEZS, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:CTIC, NASDAQ:DNDN, NASDAQ:KERX, NASDAQ:NVAX, Novavax, NVAX | Comments Off

Healthcare Sectors Optimistic Momentum Stocks- WCRX, VVUS, ARNA, RMD, BPAX, INCY, AIS

Posted on April 30, 2012 by Thomas Vedder

Warner Chilcott Plc (NASDAQ:WCRX), a maker of women’s health-care and dermatology products, surged following a news data point out the firm could be the target of a takeover by German medicine maker Bayer AG (BAYN.XE).

NASDAQ:WCRX after opening at …

Posted in Healthcare, Latest Headlines | Tagged AIS, Antares Pharma, Arena Pharmaceuticals, ARNA, Biosante, BPAX, INCY, Incyte, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:INCY, NASDAQ:VVUS, NASDAQ:WCRX, NYSE:RMD, NYSEAMEX:AIS, ResMed, RMD, Vivus, VVUS, Warner Chilcott, WCRX | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.